OptiNose Inc (NASDAQ:OPTN) – Stock analysts at Jefferies Financial Group issued their Q3 2019 EPS estimates for shares of OptiNose in a report issued on Monday, August 12th. Jefferies Financial Group analyst D. Steinberg expects that the company will post earnings of ($0.68) per share for the quarter. Jefferies Financial Group also issued estimates for OptiNose’s Q4 2019 earnings at ($0.65) EPS, FY2019 earnings at ($2.69) EPS, FY2020 earnings at ($2.00) EPS, FY2021 earnings at ($0.25) EPS, FY2022 earnings at $1.73 EPS and FY2023 earnings at $3.08 EPS.
A number of other research firms have also commented on OPTN. Zacks Investment Research lowered shares of OptiNose from a “buy” rating to a “hold” rating in a report on Thursday, July 11th. Piper Jaffray Companies set a $29.00 target price on shares of OptiNose and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Royal Bank of Canada set a $20.00 target price on shares of OptiNose and gave the stock a “buy” rating in a report on Monday, August 12th. BMO Capital Markets decreased their price target on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, ValuEngine raised shares of OptiNose from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $21.50.
OptiNose (NASDAQ:OPTN) last released its earnings results on Monday, August 12th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%. The firm had revenue of $6.68 million during the quarter, compared to analyst estimates of $7.74 million.
Hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of OptiNose by 1,569.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after buying an additional 3,766 shares during the period. Stifel Financial Corp acquired a new position in shares of OptiNose in the 4th quarter valued at $63,000. UBS Asset Management Americas Inc. acquired a new position in shares of OptiNose in the 2nd quarter valued at $72,000. Susquehanna International Group LLP acquired a new position in shares of OptiNose in the 2nd quarter valued at $77,000. Finally, Paradigm Capital Management Inc. NY acquired a new position in shares of OptiNose in the 2nd quarter valued at $78,000. 63.78% of the stock is owned by institutional investors.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.